About Us

Andlit Therapeutics is a unique biotech company, which rose from compassion and patient oriented values of Our Medison Ventures and is dedicated to developing new and innovative therapeutic agents in collaboration with partners from the industry and academia for children with HNRNPH2

Our Leadership

Meir Jakobsohn

Co-founder and President

Meir Jakobsohn founded Medison Ltd. in 1996 and spearheaded its growth as a leading international marketing group. He is the third generation of his family to help shape the local healthcare industry. Previously Meir served as the Chief Operating Officer of M. Jakobsohn Ltd. led by Arye Jakobsohn. M. Jakobsohn Ltd. was a pioneer in opening the local market to global pharmaceutical concerns like Ciba-Geigy (Novartis), which it represented between 1937 and 1995. Meir holds a BA in Economics from Bar-Ilan University and an Executive MBA from Bradford University in the UK. Meir Served in the IDF as a senior officer in the Intelligence Corps, and is constantly working in favor of various projects for the community in IsraelOfir holds a B.A in Business Management and Accounting from the College of Management. He is certified C.P.A and holds a L.L.M in Commercial Law from Bar Ilan University.

Gil Gurfinkel

Executive Chairman and Co-Founder

Gil Gurfinkel is the executive chairman and co-founder of Andlit. In parallel he is the VP corporate development of Andlit Group. Gil brings vast experience in business strategy, management consulting, corporate finance, private equity and capital markets.Prior to joining Andlit, Gil has been a Vice President at the private equity fund Shamrock Israel, where he led multiple investments and acted as a Chairman and board member of multiple Israeli and International companies. Gil holds a BSc (cum laude) from the Technion, the Israel Institute of Technology, and an MBA from the Recanati Business School at Tel Aviv University. Gil Served in the IDF as commanding officer of one of the elite units.

Yael Gruenbaum-Cohen

CEO and co-founder

Yael Gruenbaum-Cohen is CEO and co-founder of Andlit Therapeutics, and a board member of several biotech companies, particularly in the field of genetics and rare disease. Yael is also a director who leads a team of analysts in Andlit. Yael served in the IDF and is an alumna of an elite unit in the Military Intelligence Directorate; she holds academic degrees in molecular genetics (PhD, cum laude, Post doc) and a DMD from the Hebrew University of Jerusalem. Yael is a co-author of around 20 scientific publications and is highly involved in pro-bono medical and scientific support to rare disease patients.

Prof. Rotem Karni


Prof. Rotem Karni is the CTO of Andlit. Rotem serves as the chair of the Department of Biochemistry and Molecular Biology at the Institute for Medical Research, Hebrew University - Hadassah Medical School. He holds a Ph.D. in Biochemistry from the Hebrew University and was a postdoctoral fellow in the laboratory of Prof. Adrian Krainer at Cold Spring Harbor Laboratory, NY. Rotem’s research group studies the role of RNA alternative splicing in cancer development and progression. His lab is developing novel therapies that intervene in this process. Rotem is also applying his knowledge of RNA stability and splicing to search for new therapeutic approaches for rare genetic diseases. Rotem has published his research in top-tier journals and hold several patents related to the technologies he is developing.

Our Scientific Advisors

Barry Greene

Barry Greene, President of Alnylam, has more than 25 years of experience in healthcare, pharmaceutical, and biotechnology industries. Prior to Alnylam, Barry was General Manager of Oncology at Millennium Pharmaceuticals, Inc., where he led the company’s global strategy and execution for its oncology business, including strategic business direction and execution, culminating in the successful approval and launch of VELCADE® (bortezomib) in mid-2003. Prior to joining Millennium in February 2001, Barry served as Executive Vice President and Chief Business Officer for Mediconsult. Preceding that, Barry’s past experiences include Vice President of Marketing and Customer Services for AstraZeneca.

Dr. Silvi Noiman

Dr. Silvia Noiman is an entrepreneur and leading executive with over 25 years’ experience in the Life Science Industry. Prior to joining Pontifax, she was Founder and Senior Vice President at Predix Pharmaceuticals, bringing a small early-stage drug discovery company from inception to a $500M publicly traded multi-product company (EPIX). Silvia founded many of Pontifax’s portfolio companies, including cCAM Biotherapeutics (acquired by Merck) and Eloxx Pharmaceuticals (ELOX) where she served as CEO and is currently a board member. Silvia holds a Ph.D. in Molecular Biology from Tel Aviv University and Post Doc from the Weizmann Institute of Science.

Prof. Roger Kornberg

Prof. Roger Kornberg is an American biochemist and professor of structural biology at Stanford University School of Medicine. Kornberg was awarded the Nobel Prize in Chemistry in 2006 for his studies of the process by which genetic information from DNA is copied to RNA, “the molecular basis of eukaryotic transcription.”

Our Pipeline


About HNRNPH2 Mutations

HNRNP family protein can bind to heterogeneous nuclear RNAs and control the splicing fate of those RNA targets. This splicing regulation has an important role in directing cell differentiation and cell function. The splicing function on differential mRNA are controlled by shuttling complexes that bind to the HNRNP NLS domain and direct HNRNPs in and out of the nucleus. Recently, using whole exome sequencing revealed a set of de novo missense mutations that leads to a variant in HNRNPH2 protein that is associated with neurodevelopmental disorder. The HNRNPH2 gene is located on the X chromosome and most of the mutations are restricted to the NLS domain of the HNRNPH2

HNRNPH2-related disorders have recently been described in association with tone abnormalities, developmental delay, intellectual disability, autism, and seizures with a range of severity. These phenotypic observations, mainly in females, resemble many X linked mental retardation, and may have a common pathological pathway.In a mutual effort with the YBRP, we have located ~80 patients, all with de-novo mutations. Now that we have identified the causal gene responsible for the neurobehavioral challenges in these children, we have an opportunity to potentially use this gene as a target for future therapies and/or an opportunity to correct the gene through gene editing.


We are recruiting a project alliance manager, working full time to continue searching for new technologies for the
correction of HNRNPH2 mutations

  • Position: Project manager
  • Commitment: Full time

Contact us

  • Andlit Therapeutics inc.
    10 Hashiloach St,.
  • +9723950374
  • info@andlit.com

For Parents

We work closely collaboration with the Yellow Brick Road Project yellowbrickroadproject
We recommend patients and families work closely together.

Global natural history study

A global natural history study for the patients is conducted by Dr. Jennifer Bain columbianeurology at Columbia university
please see clinicaltrials